CEAPRO INC.
TSX VENTURE : CZO

CEAPRO INC.

November 14, 2007 08:15 ET

Ceapro Signs Agreement With Gamma-Dynacare Medical Laboratories for Diabetes Test, CeaProve®

EDMONTON, ALBERTA--(Marketwire - Nov. 14, 2007) - Ceapro Inc. (TSX VENTURE:CZO) announced its proprietary diabetes test meal, CeaProve® will be distributed through an agreement with Gamma-Dynacare Medical Laboratories, one of the largest and most respected medical laboratories in Canada. CeaProve® is a new and very accessible screening device, complementary to existing tests for diabetes and pre-diabetes. It will be introduced as a pilot program in selected sites in Toronto and Montreal.

Said Ceapro CEO, Dr Mark Redmond, "With epidemic increases in the incidences of diabetes - much of which can be avoided - early and regular screening for glucose intolerance is an important preventative measure. CeaProve® is the most effective, rapid and tasty screening test available."

CeaProve® consists of six highly calibrated wafers, equivalent to a balanced meal of carbohydrates, proteins and fats. This oat starch-based test has a major advantage over traditional tests in that it produces a blood glucose response that is more consistent with digestion and is reproducible, according to recent clinical studies. Also, since there is no major rise and crash of blood glucose, side effects are minimal or none.

Gamma Dynacare's Ron Hoffman, Vice-President, New Business Development says, "Gamma-Dynacare is dedicated to providing new diagnostic and screening services, that offer Canadians more options in defining and managing their health. CeaProve® will make the identification of pre-diabetic conditions easier, more accessible and more pleasant. Early detection is a key component in preventing the disease, which not only has major health benefits for Canadians, but cost savings to governments and private plans as well. " Hoffman adds, "Gamma Dynacare intends to offer CeaProve® as part of our 'wellness' portfolio of tests for executives and companies should the pilot prove successful."

If glucose intolerance is identified, early Type 2 diabetes is preventable. In December 2006, the United Nations called for concerted international action to prevent diabetes. This was followed in May 2007 by a consensus statement from the International Diabetes Foundation recommending all individuals at high risk of developing type 2 diabetes be screened and tested.

About Gamma Dynacare

Gamma-Dynacare is a nationwide provider of medical laboratory services in Canada. Each year, Gamma-Dynacare's highly qualified and dedicated technologists and technicians perform millions of tests in its state-of-the-art facilities. Gamma-Dynacare supports tens of thousands of patients, health care professionals, clinical trial sponsors, hospitals, government and various industries with its collection and transportation services, and with its comprehensive testing, screening and reporting. To learn more about Gamma-Dynacare visit www.gamma-dynacare.com.

About Ceapro Inc.

Ceapro Technology Inc., Ceapro Veterinary Products Inc., Ceapro Active Ingredients Inc. and Ceapro Bioenergy Inc. are wholly owned subsidiaries of Ceapro Inc., which is a Canadian growth-stage biotechnology company. Our primary business activities relate to the development and commercialization of organic products for medical, cosmetic and animal health industries using proprietary technology and natural, renewable resources. We will be applying our technology to become an active participant in the bioenergy sector. We have also introduced health and wellness services employing our CeaProve® diabetes screening technology. Ceapro shares trade on the Canadian TSX Venture Exchange under the symbol CZO. To learn more about Ceapro, visit www.ceapro.com .

This release may contain forward-looking statements. Various factors could cause actual results to differ materially from those projected in forward-looking statements. Although the Company believes that the forward-looking statements contained herein are reasonable, it can give no assurance that the Company's expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

The TSX Venture has neither approved nor disapproved of the information contained herein.

Contact Information

  • Ceapro Inc.
    Dr. Mark Redmond
    President and CEO
    (Edmonton): 780-421-4555
    mredmond@ceapro.com
    or
    Gamma-Dynacare Medical Laboratories
    Ron Hoffman
    V.P. New Business Development
    (Toronto): 905.790.3000 ext. 5373
    hoffmanr@gamma-dynacare.com
    or
    Sun International Communications
    Nicole Blanchard, B.Sc., B.Comm.
    Investor Relations for Ceapro
    Managing Partner
    (Montreal): 450-973-6600
    nicole.blanchard@isuncomm.com